Neuroprotective Properties of Asiatic Acid against 5-Fluorouracil Chemotherapy in the Hippocampus in an Adult Rat Model

• Published in: Nutrients 2018-08, Vol.10 (8), p.1053
• Main Authors: Welbat, Jariya Umka, Chaisawang, Pornthip, Pannangrong, Wanassanun, Wigmore, Peter
• Format: Article
• Language: English
• Subjects: 5-Fluorouracil; Acids; Animals; Antimetabolites, Antineoplastic; Antioxidants - pharmacology; asiatic acid; Behavior, Animal - drug effects; Cancer; Cell Cycle Checkpoints - drug effects; Cell number; Chemotherapy; Cyclin-dependent kinase inhibitor p21; Disease Models, Animal; Doublecortin protein; Fluorouracil; Hippocampus; Hippocampus - drug effects; Hippocampus - metabolism; Hippocampus - pathology; Hippocampus - physiopathology; Male; Malondialdehyde; Memory; Memory - drug effects; Memory Disorders - chemically induced; Memory Disorders - physiopathology; Memory Disorders - prevention & control; Memory Disorders - psychology; Molecular modelling; Nerve Tissue Proteins - metabolism; Nestin; Neurogenesis; Neurogenesis - drug effects; Neuroprotection; Neuroprotective Agents - pharmacology; Oxidative stress; Oxidative Stress - drug effects; Pentacyclic Triterpenes - pharmacology; Rats; Rats, Sprague-Dawley; Rodents; Signal Transduction - drug effects
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu10081053

5-fluorouracil or 5-FU (a chemotherapeutic medication) has been revealed to induce memory deficits in many cancer patients. Asiatic acid (AA) is a triterpenoid extract from This compound can ameliorate intracellular oxidative stress caused by chemotherapy drugs. Recent studies have shown that AA is capable of inhibiting neuronal generation and memory deficit produced by 5-FU chemotherapy. This study aimed to assess the molecular mechanisms of AA related to hippocampal neurogenesis and memory in rats receiving 5-FU. Male Sprague Dawley rats were given AA (30 mg/kg) orally and given 5-FU (25 mg/kg) by i.v. injection 5 times. Some rats were given AA for 20 days before and during 15-FU treatment (preventive), some received AA for 20 days after 5-FU treatment (recovery), and some underwent treatment with AA throughout the time of the experiment (throughout) for 40 days. Treatment with 5-FU caused significant reductions in Notch1, sex determining region Y-box 2 (SOX2), nestin, doublecortin (DCX), and nuclear factor erythroid 2-related factor 2 (Nrf2) levels within the hippocampus. In addition, 5-FU significantly increased p21 positive cell number in the subgranular zone (SGZ) and malondialdehyde (MDA) levels in the hippocampus. Administration with both AA and 5-FU in prevention and throughout was able to prevent decreases in Notch1 SOX2, nestin, DCX, and Nrf2 caused by 5-FU. Treatment with AA also led to decreases in p21 positive cells and MDA levels in the hippocampus. These findings exhibit that AA has the ability to counteract the down-regulation of neurogenesis within the hippocampus and memory deficits caused by 5-FU via inhibiting oxidative stress and increasing neuroprotective properties.